Narcolepsy Market Opportunity Analysis and Forecasts to 2027
Narcolepsy Market 2027 is a valuable source of guidance and direction for Pharma.
(EMAILWIRE.COM, September 17, 2018 ) Narcolepsy is a chronic sleep disorder characterized by two major symptoms, excessive daytime sleepiness (EDS) and cataplexy. There are two forms of narcolepsy recognized by The International Classification of Sleep Disorders: narcolepsy with cataplexy, also called narcolepsy type 1 (NT1); and narcolepsy without cataplexy, known as narcolepsy type 2 (NT2). NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus, while the cause for NT2 is still unknown and patients usually present normal levels of orexin.
There are currently few approved therapies available for narcolepsy; the majority of drugs are used off-label. Treatment needs to be tailored to the type of narcolepsy, NT1 or NT2. Current treatments centre on the management of sleepiness and cataplexy symptoms, modafinils remaining the standard of care in the treatment of sleepiness while sodium oxybate for cataplexy symptoms. These therapies provide the best relief of symptoms, with Provigil (modafinil) and Xyrem (sodium oxybate) being the two most popular branded drugs.
Get Sample Copy Of This Report at http://www.orbisresearch.com/contacts/enquiry-before-buying/2311754
GlobalData estimates that drug sales for Narcolepsy in 2017 were approximately $1.39B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $3.7B at a CAGR of 10.4%. This growth will be driven by the launch of five late-stage pipeline products. The two highest selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.
Companies Mentioned:
Teva
Jazz Pharmaceuticals
Bioproject SCR
Avadel Pharmaceuticals
GSK
Pfizer
Theranexus
Flamel Ireland
NLS Pharma
Taisho Pharmaceutical
Balance Therapeutics
Key Questions Answered
- What are the key Narcolepsy treatments in 2017?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall Narcolepsy market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Access complete report at http://www.orbisresearch.com/reports/index/narcolepsy-opportunity-analysis-and-forecasts-to-2027
Scope
- Overview of Narcolepsy, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized Narcolepsy therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (Type 1 and Type 2) forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Narcolepsy therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Narcolepsy therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global Narcolepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Narcolepsy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Narcolepsy therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2311754
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
There are currently few approved therapies available for narcolepsy; the majority of drugs are used off-label. Treatment needs to be tailored to the type of narcolepsy, NT1 or NT2. Current treatments centre on the management of sleepiness and cataplexy symptoms, modafinils remaining the standard of care in the treatment of sleepiness while sodium oxybate for cataplexy symptoms. These therapies provide the best relief of symptoms, with Provigil (modafinil) and Xyrem (sodium oxybate) being the two most popular branded drugs.
Get Sample Copy Of This Report at http://www.orbisresearch.com/contacts/enquiry-before-buying/2311754
GlobalData estimates that drug sales for Narcolepsy in 2017 were approximately $1.39B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $3.7B at a CAGR of 10.4%. This growth will be driven by the launch of five late-stage pipeline products. The two highest selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.
Companies Mentioned:
Teva
Jazz Pharmaceuticals
Bioproject SCR
Avadel Pharmaceuticals
GSK
Pfizer
Theranexus
Flamel Ireland
NLS Pharma
Taisho Pharmaceutical
Balance Therapeutics
Key Questions Answered
- What are the key Narcolepsy treatments in 2017?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall Narcolepsy market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Access complete report at http://www.orbisresearch.com/reports/index/narcolepsy-opportunity-analysis-and-forecasts-to-2027
Scope
- Overview of Narcolepsy, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized Narcolepsy therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (Type 1 and Type 2) forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Narcolepsy therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Narcolepsy therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global Narcolepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Narcolepsy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Narcolepsy therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2311754
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results